Clinical trial · no report yet · Phase 1
NCT05879978
A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3
- NCT05879978 ↗
- Active not recruiting
- Boehringer Ingelheim
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of Obrixtamig (BI 764532) Combined With Ezabenlimab in Patients With Small Cell Lung Carcinoma and Other Neuroendocrine Neoplasms Expressing DLL3
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Small Cell Lung Carcinoma (SCLC); Neuroendocrine Neoplasms
- Interventions
- Obrixtamig; Ezabenlimab
- Arms
- obrixtamig + ezabenlimab treatment group · Experimental
- Enrollment
- 45
- Primary outcomes
- Occurrence of Dose Limiting Toxicities (DLTs) in the Maximum Tolerated Dose (MTD) evaluation period
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 27, 2023
- Primary completion
- Jun 11, 2025
- Results posted
- No
- Registry record
- NCT05879978 · updated Aug 4, 2026